N-of-1 Tests in General Practice: Pharmacological Considerations

Overview

Journal Br J Gen Pract

Specialty Public Health

Date 2025 Feb 27

PMID 40016097

Authors

Leonore Diezi

Marco Anastasi

Laurent Brutus

Thierry Buclin

Affiliations

Soon will be listed here.

References

Guyatt G, Keller J, Jaeschke R, Rosenbloom D, Adachi J, Newhouse M . The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann Intern Med. 1990; 112(4):293-9. DOI: 10.7326/0003-4819-112-4-293. View

Goyal P, Safford M, Hilmer S, Steinman M, Matlock D, Maurer M . N-of-1 trials to facilitate evidence-based deprescribing: Rationale and case study. Br J Clin Pharmacol. 2022; 88(10):4460-4473. PMC: 9464693. DOI: 10.1111/bcp.15442. View

Stunnenberg B, Berends J, Griggs R, Statland J, Drost G, Nikles J . N-of-1 Trials in Neurology: A Systematic Review. Neurology. 2021; 98(2):e174-e185. DOI: 10.1212/WNL.0000000000012998. View

Lasserson D, Buclin T, Glasziou P . How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart. 2011; 97(21):1771-5. DOI: 10.1136/hrt.2010.221473. View

Patil S, Kuchekar B, Chabukswar A, Jagdale S . Formulation and evaluation of extended-release solid dispersion of metformin hydrochloride. J Young Pharm. 2011; 2(2):121-9. PMC: 3021685. DOI: 10.4103/0975-1483.63147. View

Mirza R, Punja S, Vohra S, Guyatt G . The history and development of N-of-1 trials. J R Soc Med. 2017; 110(8):330-340. PMC: 5546658. DOI: 10.1177/0141076817721131. View

Wernicke J, Pritchett Y, DSouza D, Waninger A, Tran P, Iyengar S . A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006; 67(8):1411-20. DOI: 10.1212/01.wnl.0000240225.04000.1a. View

He W, Cui Z, Chen Y, Wang F, Li F . Status of N-of-1 Trials in Chronic Pain Management: A Narrative Review. Pain Ther. 2021; 10(2):1013-1028. PMC: 8586287. DOI: 10.1007/s40122-021-00314-4. View

Kravitz R, Paterniti D, Hay M, Subramanian S, Dean D, Weisner T . Marketing therapeutic precision: Potential facilitators and barriers to adoption of n-of-1 trials. Contemp Clin Trials. 2009; 30(5):436-45. DOI: 10.1016/j.cct.2009.04.001. View

10.

Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid C, Tate R . CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. J Clin Epidemiol. 2015; 76:9-17. DOI: 10.1016/j.jclinepi.2015.05.004. View

11.

Wood F, Howard J, Finegold J, Nowbar A, Thompson D, Arnold A . N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med. 2020; 383(22):2182-2184. DOI: 10.1056/NEJMc2031173. View

12.

Zucker D, Ruthazer R, Schmid C, Feuer J, Fischer P, Kieval R . Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. J Rheumatol. 2006; 33(10):2069-77. View

13.

Gabler N, Duan N, Vohra S, Kravitz R . N-of-1 trials in the medical literature: a systematic review. Med Care. 2011; 49(8):761-8. DOI: 10.1097/MLR.0b013e318215d90d. View

14.

Kronish I, Hampsey M, Falzon L, Konrad B, Davidson K . Personalized (N-of-1) Trials for Depression: A Systematic Review. J Clin Psychopharmacol. 2018; 38(3):218-225. PMC: 5904006. DOI: 10.1097/JCP.0000000000000864. View

15.

Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A . Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021; 372:n135. PMC: 7903384. DOI: 10.1136/bmj.n135. View